Sun Pharma Advanced Research Company (SPARC) has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a significant surge in annual performance, driven largely by the recognition of income from a Priority Review Voucher (PRV). The company recorded a standalone annual profit of ₹1,55,213 Lakhs, marking a substantial turnaround compared to the previous fiscal year.
Financial Highlights for FY26
For the financial year ended March 31, 2026, SPARC reported a robust standalone total income of ₹1,89,000 Lakhs. This performance marks a major shift for the company, resulting in a standalone profit after tax of ₹1,55,213 Lakhs, compared to a loss of ₹34,522 Lakhs in the previous fiscal year. Consolidated results followed a similar positive trend, with a profit after tax of ₹1,55,320 Lakhs.
Strategic Revenue Drivers
The primary driver for this exceptional growth was the recognition of ₹1,84,002 Lakhs in other operating revenue during the final quarter of the fiscal year. This income was derived from a Priority Review Voucher (PRV) granted by the USFDA on February 3, 2026, for the company’s product, Sezaby®. As a transferable asset, this PRV was subsequently sold for USD 195 million on April 30, 2026.
Performance Overview
Quarterly performance for the period ended March 31, 2026, reflected the impact of this one-time gain, with standalone revenue from operations reaching ₹1,85,322 Lakhs. While the company incurred total expenses of ₹32,551 Lakhs for the full year, the strategic monetization of the PRV has significantly strengthened the company’s balance sheet and equity position. The company maintains its focus on its core business segment of Pharmaceutical Research and Development.
Source: BSE
